Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
about
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple MyelomaGalectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myelomaTargeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaPSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneMLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells.Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion.Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition
P2860
Q28243388-3609D94B-686E-47D8-A4B8-47D09FA93C3BQ28534603-40856AA6-B931-4B0C-A03F-6E225F01655DQ28742668-0F588471-89F6-4E04-A4B1-21C87FBE81A1Q33585280-59C29DDB-0FE3-4F00-A4C5-4685C758B972Q36333522-5D12B049-99FD-4166-B3E7-FF3B42597BCEQ36444233-F6FA44F4-9186-443F-9512-2840C6B64D9BQ36839558-9CF52262-264E-4B03-A317-EC9B9A383314Q37132862-30528FB7-A46D-453D-9FBA-115070A68039Q38026589-D60519AA-74AA-49FA-A820-A3B88D13C981Q38895636-139495E8-A0E3-43D9-964B-6B8133026DBFQ39689809-EEE24FAF-1D79-4227-9F8E-85BF986449AEQ39748970-F9DD7B80-94B8-42F3-82F7-DAC11321E3C3Q46667078-C04B35EA-1EE7-490E-9302-11DDDF86F11CQ57163862-C439C59C-843A-46D4-AF88-5D94D22FA824
P2860
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clinical challenges associated ...... Waldenströms Macroglobulinemia
@ast
Clinical challenges associated ...... Waldenströms Macroglobulinemia
@en
type
label
Clinical challenges associated ...... Waldenströms Macroglobulinemia
@ast
Clinical challenges associated ...... Waldenströms Macroglobulinemia
@en
prefLabel
Clinical challenges associated ...... Waldenströms Macroglobulinemia
@ast
Clinical challenges associated ...... Waldenströms Macroglobulinemia
@en
P2093
P2860
P1433
P1476
Clinical challenges associated ...... Waldenströms Macroglobulinemia
@en
P2093
Aldo M Roccaro
Constantine S Mitsiades
Irene M Ghobrial
Jacob P Laubach
P2860
P304
P356
10.1080/10428190902866732
P577
2009-05-01T00:00:00Z